DiaMedica to Present at the 14th Annual BIO CEO and Investor Conference

DiaMedica Inc. (TSX VENTURE:DMA) a biopharmaceutical company focused on the
development of novel treatments for Type 1 and Type 2 diabetes announced today
that Mr. Rick Pauls, DiaMedica's President and Chief Executive Officer, will
present at the 2012 BIO CEO & Investor Conference in New York on Monday,
February 13, 2012 at 4:30 p.m. Eastern Time at the Waldorf-Astoria in New York
City. At the conference, which is hosted by the Biotechnology Industry
Organization (BIO), Mr. Pauls will provide an overview of DiaMedica's diabetes
programs.


About BIO CEO & Investor Conference 

The BIO CEO & Investor Conference is the largest independent investor conference
focused on publicly-traded biotechnology companies. The conference provides a
forum where institutional investors, industry analysts, and senior biotechnology
executives have the opportunity to shape the future investment landscape of the
biotechnology industry through issue-oriented plenary sessions, educational
sessions focused on hot therapeutic areas and key business issues, company
presentations, and one-on-one meetings. 


About DiaMedica 

DiaMedica is a biopharmaceutical company focused on discovery and development of
novel therapeutic compounds for diabetes and other major, medically-unmet
diseases. DiaMedica's lead compound, DM-199, is a recombinant human protein that
represents a novel approach to treating Type 1 and Type 2 diabetes. In a Type 1
diabetes model, DM-199 halted the autoimmune attack on beta cells by stimulating
regulatory T-cells, and resulted in a 12-fold increase in C-peptide levels. In
Type 2 diabetes models, DM-199 treatment stimulated proliferation of insulin
producing beta cells and significant improvement in glucose control.


DiaMedica is also developing a novel monoclonal antibody, DM-204 as a treatment
for Type 2 diabetes. Chronic treatment with DM-204 in a Type 2 diabetes model
resulted in significant improvement in blood glucose control and HbA1c levels
and also significant decreases in blood pressure and serum cholesterol.


Both DM-199 and DM-204 have proven efficacious in treating several other,
non-diabetes related, disease models.


The company is listed on the TSX Venture Exchange under the trading symbol 'DMA'. 

Caution Regarding Forward-Looking Information

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.